Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.23
-1.27 (-4.98%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Damora Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 9.69 | 10.5 | 12.69 | 13 | 13.74 | |
| Research & Development | 26.88 | 6.4 | 23.77 | 48.21 | 38.49 | |
| Operating Expenses | 36.56 | 16.9 | 36.46 | 61.21 | 52.23 | |
| Operating Income | -36.56 | -16.9 | -36.46 | -61.21 | -52.23 | |
| Interest & Investment Income | 1.17 | 0.91 | 1.26 | 1.29 | 1.23 | |
| Currency Exchange Gain (Loss) | -0.08 | 0.02 | -0.2 | -1.07 | 0.32 | |
| EBT Excluding Unusual Items | -35.48 | -15.97 | -35.4 | -60.99 | -50.68 | |
| Merger & Restructuring Charges | - | -0.97 | -3.45 | - | - | |
| Gain (Loss) on Sale of Investments | - | -0.07 | 0.43 | -0.64 | -1.07 | |
| Gain (Loss) on Sale of Assets | - | - | 0.06 | - | - | |
| Pretax Income | -209.79 | -21.4 | -38.35 | -61.62 | -51.75 | |
| Income Tax Expense | 0.05 | 0.04 | - | - | - | |
| Net Income | -209.84 | -21.44 | -38.35 | -61.62 | -51.75 | |
| Net Income to Common | -209.84 | -21.44 | -38.35 | -61.62 | -51.75 | |
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | |
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | |
| Shares Change (YoY) | 17.79% | 8.87% | 4.58% | 0.58% | 452.45% | |
| EPS (Basic) | -153.95 | -18.53 | -36.08 | -60.63 | -51.22 | |
| EPS (Diluted) | -153.95 | -18.53 | -36.08 | -60.63 | -51.22 | |
| Free Cash Flow | -6.73 | -18.62 | -36.91 | -43.13 | -52.53 | |
| Free Cash Flow Per Share | -4.93 | -16.09 | -34.73 | -42.43 | -51.99 | |
| EBITDA | -36.54 | -16.88 | -36.19 | -61.17 | -52.21 | |
| D&A For EBITDA | 0.02 | 0.02 | 0.27 | 0.04 | 0.02 | |
| EBIT | -36.56 | -16.9 | -36.46 | -61.21 | -52.23 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.